Roche hails an­oth­er PhI­II win on Tecen­triq com­bo, re­ports promis­ing kid­ney can­cer da­ta

Roche is ped­al­ing hard from be­hind in the race for PD-1/L1 mar­ket su­prema­cy, an­nounc­ing news at mar­ket close Mon­day that it’s wrapped up yet an­oth­er promis­ing Phase III com­bo study us­ing Tecen­triq.

With heavy­weights like Mer­ck and Bris­tol-My­ers Squibb lead­ing the mar­ket, Roche $RHH­BY and its sub­sidiary Genen­tech are step­ping up their game. The lat­est Phase III study test­ed Tecen­triq with Avastin against ad­vanced or metasta­t­ic re­nal cell car­ci­no­ma or kid­ney can­cer.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.